Amgen (AMGN) Looking Over Takeover Offer for Swiss Drugmaker Actelion
Tweet
Share
E-mailGet Alerts AMGN Hot Sheet
Join SI Premium – FREE
Amgen Inc. (NASDAQ: AMGN) is studying its takeover offer for Swiss drugmaker Actelion, and the company may approach its target as soon as this week, according to a report from Bloomberg citing people familiar with the matter.
The report noted that Actelion recently learned of the potential bid from Amgen. Actelion has a market value of 6.5 billion Swiss francs ($6.5 billion).
The Swiss company is the world's largest maker of pulmonary hypertension drugs. The company may generate revenue of $2.1 billion by 2015 from Tracleer.
One of the sources cited by Bloomberg said that Amgen has not made a final decision about making an offer for Actelion.
Shares of Amgen are down 46 cents to $54.05 in midday market movement on Tuesday.
The report noted that Actelion recently learned of the potential bid from Amgen. Actelion has a market value of 6.5 billion Swiss francs ($6.5 billion).
The Swiss company is the world's largest maker of pulmonary hypertension drugs. The company may generate revenue of $2.1 billion by 2015 from Tracleer.
One of the sources cited by Bloomberg said that Amgen has not made a final decision about making an offer for Actelion.
Shares of Amgen are down 46 cents to $54.05 in midday market movement on Tuesday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Amgen (AMGN) PT Raised to $343 at Guggenheim
- Amgen (AMGN) PT Raised to $312 at BofA Securities
- Voya Financial Fielded Takeover Interest In Recent Weeks - Semafor
Create E-mail Alert Related Categories
Insiders' Blog, RumorsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
